Merck & Co., Inc. (NYSE:MRK) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $87.99 and last traded at $86.85, with a volume of 548034 shares trading hands. The stock had previously closed at $87.18.
MRK has been the topic of a number of recent research reports. Mizuho boosted their target price on Merck & Co., Inc. from $97.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Leerink Swann assumed coverage on Merck & Co., Inc. in a research note on Thursday, August 15th. They set an “outperform” rating and a $103.00 price target for the company. Svb Leerink initiated coverage on Merck & Co., Inc. in a report on Friday, August 16th. They set an “outperform” rating and a $103.00 price target for the company. JPMorgan Chase & Co. set a $96.00 price target on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, October 10th. Finally, Credit Suisse Group restated a “buy” rating and issued a $95.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $95.47.
The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 0.84. The business has a 50-day simple moving average of $84.54 and a 200-day simple moving average of $83.57. The stock has a market cap of $221.96 billion, a P/E ratio of 20.01, a PEG ratio of 1.89 and a beta of 0.52.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 8th. Investors of record on Monday, December 16th will be paid a $0.61 dividend. The ex-dividend date is Friday, December 13th. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.55. This represents a $2.44 dividend on an annualized basis and a yield of 2.81%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.69%.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Titan Capital Management LLC CA acquired a new position in shares of Merck & Co., Inc. during the second quarter worth approximately $25,000. LFA Lugano Financial Advisors SA grew its stake in shares of Merck & Co., Inc. by 250.0% in the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after acquiring an additional 225 shares during the last quarter. JJJ Advisors Inc. acquired a new stake in shares of Merck & Co., Inc. in the second quarter worth $27,000. Cumberland Partners Ltd bought a new position in Merck & Co., Inc. during the second quarter worth $40,000. Finally, Fusion Family Wealth LLC increased its position in Merck & Co., Inc. by 268.2% during the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after acquiring an additional 354 shares during the period. Hedge funds and other institutional investors own 74.53% of the company’s stock.
Merck & Co., Inc. Company Profile (NYSE:MRK)
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
See Also: How prevalent are 12b-1 fees?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.